Recently, anti-VEGF treatment with bevacizumab has been shown to be effective in treating ROP in the BEATROP trial2, which showed that vascularization was completed 19.5 weeks after intravitreal bevacizumab (IVB). Here, VEGFA is linked to retinopathy of prematurity.